Compositions and methods for increasing telomerase activity
The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
1. A method of increasing telomerase activity in a cell or tissue, comprising:
identifying a cell or tissue in which an increase in telomerase activity is desired, and contacting said cell or tissue with a formulation of an isolated compound of formula II:
where:
X 4 is hydroxy or β-D-xylopyranoside;
X 5 is hydroxy, or keto, and
OR 3 is hydroxy.
2. The method of claim 1 , wherein X 5 is OH.
3. A method of increasing telomerase activity in a cell or tissue, comprising:
identifying a cell or tissue in which an increase in telomerase activity is desired, and contacting said cell or tissue with a formulation of an isolated compound of formula III:
where:
X 6 is hydroxy or β-D-glucopyranoside,
X 7 is hydroxy or β-D-glucopyranoside, and
X 8 is hydroxy, and
OR 4 is hydroxy or β-D-glucopyranoside.
4. A method of treating a condition in a patient associated with accelerated telomere repeat loss by increasing telomerase activity in cells or tissue of said patient, comprising administering to a patient in need of such treatment, a formulation of an effective amount of formula II, as defined in claim 1 .
5. The method of claim 4 , wherein said condition is HIV infection or a degenerative disease.
6. The method of claim 4 , wherein said degenerative disease is selected from the group consisting of a neurodegenerative disease, a degenerative disease of the bones or joints, macular degeneration, atherosclerosis, and anemia.
7. The method of claim 4 , wherein said condition is an acute or chronic condition of the epidermis.
8. A pharmaceutical composition comprising, in a pharmaceutically acceptable vehicle, a compound of formula II:
where:
X 4 is hydroxy or β-D-glucopyranoside;
X 5 is hydroxy, or, keto, and
OR 3 is hydroxy.
9. The composition of claim 8 , wherein said compound is present in said composition at a concentration of at least 0.1% (w/v).
10. A method of treating an acute or chronic condition of the epidermis, comprising contacting epidermal cells with a topical formulation of an isolated compound of formula II, as defined in claim 1 .
11. The method of claim 10 , wherein said acute or chronic condition is selected from the group consisting of a wound, a burn, an abrasion, an incision, a graft site, a lesion caused by an infectious agent, a chronic venous ulcer, a diabetic ulcer, a compression ulcer, a pressure sores, a mucosal ulcer, and keloid formation.
12. A pharmaceutical composition comprising a topical formulation of an isolated compound of formula II, as defined in claim 1 .
13. The composition of claim 12 , wherein said compound is present in said formulation at a concentration of at least 0.1% (w/v).
14. The composition of claim 12 , wherein said topical formulation comprises one or more components selected from the group consisting of an emulsifier, a thickener, and a skin emollient.
15. The method of claim 1 , wherein said compound is 20R,24S-epoxy-3β,16β,25-trihydroxy-9β-methyl-19-norlanost-1,5-diene (designated herein as 5).
16. A method of enhancing replicative capacity of cells in vitro or ex vivo, comprising contacting said cells with a compound of formula II, as defined in claim 1 in an amount effective to increase telomerase activity in said cells.
17. The method of claim 16 , wherein said cells are explant cells obtained from a patient.
18. The method of claim 16 , wherein said cells are stem cells.
19. The method of claim 16 , wherein said cells are selected from bone marrow stromal cells, adrenocortical cells, muscle satellite cells, osteoblasts, retinal pigmented epithelial cells, and chondrocytes.
20. A nutraceutical composition comprising a nutraceutical formulation of an isolated compound of formula II, as defined in claim 1 .
21. The composition of claim 20 , wherein said isolated compound is present in said formulation at a concentration of at least 0.1% (w/v).
22. An isolated compound of formula II:
where:
X 4 is hydroxy or β-D-xylopyranoside;
X 5 is hydroxy, or keto, and
OR 3 is hydroxy.
23. The compound of claim 22 , wherein X 4 is OH or β-D-xylopyranoside and each of X 5 and OR 3 is OH.
24. The compound of claim 23 , wherein the compound is 20R,24S-epoxy-3β,16β,25-trihydroxy-9β-methyl-19-norlanost-1,5-diene (designated herein as 5).
25. The method of claim 3 , wherein the compound includes zero or one β-D-glycopyranosides.
26. The method of claim 3 , wherein the compound is ginsenoside RH1.
27. A method of treating a condition in a patient by increasing telomerase activity in cells or tissue of said patient, comprising administering to a patient in need of such treatment, a formulation of an effective amount of formula III, as defined in claim 3 .
28. A method of treating an acute or chronic condition of the epidermis, comprising contacting epidermal cells with a topical formulation of an isolated compound of formula III, as defined in claim 3 .
29. A method of enhancing replicative capacity of cells in vitro or ex vivo, comprising contacting said cells with a compound of formula III, as defined in claim 3 in an amount effective to increase telomerase activity in said cells.
30. A nutraceutical composition comprising a nutraceutical formulation of an isolated compound of formula III,
where:
X 6 is hydroxy or β-D-glucopyranoside,
X 7 is hydroxy, and
X 8 is hydroxy, and
OR 4 is hydroxy or β-D-glucopyranoside.